A Registry for People With Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-15

Study Completion Date

2029-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Lung Cancer Stage I

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

lung cancer lung cancer stage 1 segmentectomy Memorial Sloan Kettering Cancer Center 24-127

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Lung Cancer

Participants undergoing planned pulmonary segmentectomy for primary lung cancer

Patient-Reported Outcomes Measurement Information System

Intervention Type OTHER

Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patient-Reported Outcomes Measurement Information System

Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PROMIS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology

Exclusion Criteria

* Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years
* History of chemotherapy or radiation therapy for a previous lung cancer
* Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery
* Carcinoid tumors
* History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
* Actively receiving treatment for other malignancies
* Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.

* Multi-segmental resection from the same lobe is not a criterion for exclusion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Jones, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Reach out to these primary contacts for questions about participation or study logistics.

David Jones, MD

Role: CONTACT

Phone: 212-639-6428

Identifier Type: -

Identifier Source: org_study_id

A Registry for People With Lung Cancer

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Participants with Lung Cancer

Patient-Reported Outcomes Measurement Information System

Interventions

Patient-Reported Outcomes Measurement Information System

Other Intervention Names

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Memorial Sloan Kettering Cancer Center

Responsible Party

Principal Investigators

David Jones, MD

Locations

Rush University Medical Center (Data collection only)

Endeavor Health

University of Michigan (Data Collection Only)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

ALLEGHENY HEALTH NETWORK (Data Collection Only)

MD Anderson Cancer Center (Data Collection Only)

University Health Network (Data Collection Only)

Centre Hospitalier de l'Université de Montreal (Data Collection Only)

Countries

Central Contacts

David Jones, MD

Bernard Park, MD

Facility Contacts

Christopher Seder, MD

Seth Krantz, MD

Jules Lin, MD

David Jones, MD

David Jones, MD

David Jones, MD

David Jones, MD

David Jones, MD

David Jones, MD

Yuan Liu, MD, PhD

David Jones, MD

Benny Weksler, MD

David Rice, MD

Elliot Wakeam, MD

Moishe Liberman, MD. PhD

Related Links

Other Identifiers

24-127